Sort
23,748 grants matching “melanoma”
Primary Project
$225,908Eva M Sevick-Muraca · University Of Texas Hlth Sci Ctr Houston · U54 · FY2008 · CA
Oncogene Mutation Profiling in Uveal Melanoma
$225,908Ivana Kim · Massachusetts Eye And Ear Infirmary · R21 · FY2010 · CA
Pilot Study of Arsenic, UV and Melanoma in a Non-Hispanic White Population
$225,875Janice W Yager · University Of New Mexico Health Scis Ctr · R21 · FY2010 · ES
Cell Culture Core
$225,798Ruth Halaban · Yale University · P30 · FY2008 · AR
Analytical Chemistry and Pharmacology Core Facility
$225,770William C Zamboni · Univ Of North Carolina Chapel Hill · P30 · FY2014 · CA
Comparative Assessment of Screening Strategies for Melanoma
$225,765Sandra J Lee · Dana-Farber Cancer Inst · R21 · FY2015 · CA
Cbx-3/HP-1gamma deficiency confers anti-tumor immunity
$225,765To-Ha Thai · Beth Israel Deaconess Medical Center · R21 · FY2017 · CA
Radiometal Chelates for Targeted Therapy of Melanoma
$225,720Lynn Carol Francesconi · Hunter College · SC1 · FY2011 · CA
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$225,703John Tanner Wilson · Vanderbilt University · R01 · FY2025 · CA
Targeting alfa 1beta1 integrin in cancer development
$225,675Temple University · R01 · FY2004 · CA
SIGNALING MECHANISMS FOR WNT PROTEINS
$225,585University Of Connecticut Sch Of Med/Dnt · R01 · FY2002 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$225,566Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2024 · CA
Tumor therapy with antiangiogenic beta-2-glycoprotein 1
$225,502Alan Jay Schroit · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Tumor therapy with antiangiogenic beta-2-glycoprotein 1
$225,502Alan Jay Schroit · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
Dendritoma Vaccine on Renal Cell Carcinoma
$225,500Greenville General Hospital · R21 · FY2004 · CA
NCI Patterns of Care (POC)/Quality of Care Study: Diagnosis Years 2017(NSCLC) and 2018 (NSCLC and Melanoma)
$225,471Rosemary Cress · Public Health Institute · N01 · FY2019 · CA
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMA
$225,465James W Harbour · Washington University · R01 · FY2010 · CA
Community Outreach and Engagement (COE)
$225,396Monica Yellowhair · University Of Arizona · P30 · FY2025 · CA
PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA
$225,371University Of Pittsburgh At Pittsburgh · R01 · FY2002 · CA
Mechanisms Linking Metastasis to Tumor Procoagulant and Innate Immunity
$225,351Joseph S Palumbo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2009 · HL
Regulation of cell homeostasis by fbx4
$225,349J. Alan Diehl · Medical University Of South Carolina · R01 · FY2014 · CA
MODIFICATION OF HYPERTHERMIA RESPONSE
$225,338Thomas Jefferson University · P01 · FY2003 · CA
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE
$225,335Joseph Anthoney Vetro · University Of Nebraska Medical Center · P20 · FY2010 · RR
Effects of a Novel Phospho-STAT2 inhibitor for Treatment of Stage IV Melanoma
$225,296Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · P50 · FY2012 · CA
Effect of oncolytic herpesvirus on the tumor microenvironment
$225,148Paul Rider · Lsu Health Sciences Center · P20 · FY2020 · GM